Skip to main content

Table 2 Relative hazard of death in HNSCC patients based on platelet counts

From: Lower circulating platelet counts and antiplatelet therapy independently predict better outcomes in patients with head and neck squamous cell carcinoma

Variables Low (<150) N = 67 Low normal (150-229) N = 361 Mid-normal (230-314) N = 379 High normal (315-399) N = 169 HIGH (≥400) N = 75
Number dead (%) 37 (55) 150 (42) 146 (39) 105 (62) 53 (71)
Median Survival Months (95% CI) 37.7 (20.7- 84.8) 64.0 (53.6-78.9) 74.7 (60.7 100.4) 23.8 (17.7 - 36.7) 16.3 (11.8 -29.2)
p-value for difference      <0.0001
Overall Survival      
Unadjusted HR (95% CI) 1.52 (1.06-2.18) 1.07 (0.85-1.34) 1.0 (reference) 1.98 (1.54-2.55) 2.64 (1.92 -3.61)
Adjusted HR (95% CI) 1.50 (0.96-2.35) 1.25 (0.93-1.68) 1.0 (reference) 2.20 (1.58-3.05) 2.37 (1.60-3.50)
HR (95% CI) by Stage      
I (n = 103) 0.41 (0.05-.3.31) 1.18 (0.33-4.20) 1.0 (reference) 1.60 (0.27-9.54) 0.35 (0.03-4.18)
II (n = 95) 1.99 (0.52-7.67) 1.40 (0.57-3.38) 1.0 (reference) 1.54 (0.48-4.99) 1.83 (0.45-7.40)
III (n = 146) 0.74 (0.16-3.40) 1.32 (0.62-2.82) 1.0 (reference) 2.43 (0.91-6.50) 1.86 (0.53-6.45)
IV (n = 478) 2.33 (1.34-4.10) 1.18 (0.78-1.78) 1.0 (reference) 2.50 (1.66-3.76) 2.47 (1.55-2.93)
  1. Adjusted model controls for age, race, site, grade, treatment, smoking and stage.
  2. P for interaction between stage and classes of platelets p = 0.31.